Protara Therapeutics, Inc. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
Protara Therapeutics, Inc. (TARA) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $6.34 million as of 2024-12-31, per its 10-K filed 2025-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2025-03-05
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $6.34M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.46M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $2.48M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $920.00K.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2024-12-31 | $6.34M 10-K · filed 2025-03-05 |
| 2023-12-31 | $4.46M 10-K · filed 2025-03-05 |
| 2022-12-31 | $2.48M 10-K · filed 2024-03-13 |
| 2021-12-31 | $920.00K 10-K · filed 2023-03-08 |
| 2020-12-31 | $443.00K 10-K · filed 2022-03-09 |
| 2018-12-31 | $1.78M 10-K · filed 2020-03-20 |
| 2017-12-31 | $1.26M 10-K · filed 2019-03-13 |
| 2016-12-31 | $1.35M 10-K · filed 2019-03-13 |
| 2015-12-31 | $596.00K 10-K · filed 2018-03-14 |
| 2014-12-31 | $92.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |